Cue Biopharma (CUE) Free Cash Flow (2017 - 2025)
Cue Biopharma (CUE) posted Free Cash Flow of -$1.1 million for Q4 2025, up 88.08% sequentially from -$9.0 million in Q3 2025, and up 88.08% YoY from -$572084.3 in Q4 2024.
Cue Biopharma (CUE) Free Cash Flow (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Free Cash Flow for 9 years, with the latest figure at -$1.1 million in Q4 2025.
- Quarterly Free Cash Flow rose 88.08% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$21.9 million (up 39.93% YoY) and the FY2025 annual result came in at -$21.9 million, up 39.93% from the prior year.
- Free Cash Flow improved to -$1.1 million in Q4 2025 per CUE's latest filing, from -$9.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.1 million in Q4 2025 and troughed at -$12.9 million in Q2 2022.
- A 5-year average of -$9.0 million and a median of -$9.9 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 91.79% in 2021, down 107.5% in 2021.
- Over 5 years, Free Cash Flow stood at -$10.6 million in 2021, then rose by 1.22% to -$10.5 million in 2022, then dropped by 4.21% to -$11.0 million in 2023, then climbed by 17.59% to -$9.0 million in 2024, then jumped by 88.08% to -$1.1 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.1 million, -$9.0 million, and -$3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | -8.32 Mn |
| Mar 31, 2025 | -8.32 Mn |
| Dec 31, 2024 | -9.03 Mn |
| Dec 31, 2024 | -9.03 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -10.00 Mn |
| Jun 30, 2024 | -10.00 Mn |
| Mar 31, 2024 | -9.84 Mn |
| Mar 31, 2024 | -9.84 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -7.80 Mn |
| Sep 30, 2023 | -7.80 Mn |